Marker Therapeutics, Inc. (MRKR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 53/100 (HIGH), 8.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.22% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
- New Strong Buy Stocks for October 16th
- Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
- High Growth Tech Stocks To Watch In US June 2026
- Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
- Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
- Exploring 3 High Growth Tech Stocks In The US Market
- US High Growth Tech Stocks with Promising Potential
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Immunoglobulin GM (γ marker) allotypes as potential genetic markers of efficacy of lecanemab therapy in Alzheimer's disease. — J Alzheimers Dis 2026 Oct 16 PMID 42885677
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Marker Therapeutics, Inc..
Full MRKR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.